Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease - Trial NCT05811442
Access comprehensive clinical trial information for NCT05811442 through Pure Global AI's free database. This Phase 2 trial is sponsored by Beijing Joekai Biotechnology LLC and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing Joekai Biotechnology LLC
Timeline & Enrollment
Phase 2
Apr 01, 2023
Jun 01, 2024
Primary Outcome
Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog 13)
Summary
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study
 designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in
 participants diagnosed with mild to moderate Alzheimer's disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05811442
Non-Device Trial